Evaluation of exercise capacity with cardiopulmonary exercise test and B-type natriuretic peptide in adults with congenital heart disease

Cardiology Journal

Volumn 16, Issue 2, 2009, Pages 133-141

  Trojnarska, Olga ^a   Gwizdała, Adrian ^a   Katarzyński, Sławomir ^a   Katarzyńska, Agnieszka ^a   Szyszka, Andrzej ^a   Lanocha, Magdalena ^a   Grajek, Stefan ^a   Kramer, Lucyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cardiopulmonary exercise testing; Congenital heart disease; Natriuretic peptide type B

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER;

ADULT; AGED; AORTA COARCTATION; ARTICLE; CARDIOPULMONARY EXERCISE TEST; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYANOSIS; EBSTEIN ANOMALY; EISENMENGER COMPLEX; EXERCISE; EXERCISE TOLERANCE; FALLOT TETRALOGY; FEMALE; FORCED EXPIRATORY VOLUME; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART INJURY; HEART PERFORMANCE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PHYSICAL CAPACITY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RESPIRATION LOAD; BLOOD; BREATHING; CASE CONTROL STUDY; CONGENITAL HEART MALFORMATION; EXERCISE TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SPIROMETRY; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEART DEFECTS, CONGENITAL; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATION; SPIROMETRY; UP-REGULATION; YOUNG ADULT;

EID: 66349117791     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fredriksen G, Hechter S, Therrien J et al. Aerobic capacity in adults with various congenital heart disease. Am J Cardiol, 2001; 87: 310-314.
2. Trojnarska O, Szyszka A, Gwizdala A et al. Evaluation of exercise capacity with cardiopulmonary exercise testing and with type B natriuretic peptide concentration in adults patients with patent atrial septal defect. Cardiology, 2006; 106: 154-162.
3. Trojnarska O, Szyszka A, Gwizdala A et al. The BNP concentration and exercise capacity assessment with cardiopulmonary stress test in patients after surgical repair of Fallot's tetralogy. Int J Cardiol, 2006; 110: 86-92.
4. Trojnarska O, Szyszka A, Gwizdala A et al. Adults with Ebstein anomaly cardiopulmonary exercise testing and BNP level. Int J Cardiol, 2006; 111: 92-97.
5. Trojnarska O, Gwizdala A, Lanocha M et al. Cardiopulmonary exercise testing in the evaluation of exercise capacity and B-type natriuretic protein level in adult patients after repair of coarctation of aorta. Tex Heart Inst J, 2007; 34: 412-419.
6. Bolger AP, Sharma R, Lei W et al. Neurohormonal activation and chronic heart failure syndrome in adults with congenital heart disease. Circulation, 2002; 106: 92-99.
7. Bolger AP, Coats AJ, Gatzoulis MA. Congenital heart disease: The original heart failure syndrome. Eur Heart J, 2003; 24: 970-976.
8. Bolger AP, Gatzoulis MA. Towards definition heart failure in adults with congenital heart disease. Int J Cardiol, 2004; 97: 15-23.
9. Trojnarska O. Heart failure in the adult patient with congenital heart disease. Cardiol J, 2007; 14: 127-137.
10. Book WM. Heart failure in the adult patients with congenital heart disease. J Card Fail, 2005; 11: 306-312.
11. Gillian T, Eriksson BP, Sixt R. Cardiac output and pulmonary gas exchange at maximal exercise after atrial redirection for complete transposition. Eur Heart J, 1998; 19: 1856-1864.
12. Glaser S, Opitz CF, Bauer U et al. Assessment of symptoms and exercise capacity in cyanotic patients with congenital heart disease. Chest, 2004: 125: 368-376.
13. Dimopoulos K, Okonko DO, Diller GP et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predict survival. Circulation, 2006; 113: 2796-2802.
14. Diller GP, Dimopoulos K, Okonko D et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol, 2006: 48: 1250-1256.
15. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation, 2007; 115: 1039-1050.
16. Dore A, Houde C, Chan KL et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricle. Circulation, 2005; 112: 2411-2416.
17. Oosterhof T, Tulewski II, Vliegen HW, Spijkerboer CF, Mudler BJM. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol, 2006; 97: 1051-1055.
18. Guidelines for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Eur Heart J, 2005; 26: 1115-1140.
19. Diller GP, Dimopoulos K, Okonko D et al. Exercise intolerance in adult congenital heart disease. Circulation, 2005; 112: 828-835.
20. Giardini A, Scecchia S, Berton E et al. Strong and independent prognostic value of peak circulatory power in adults with congenital heart disease. Am Heart J, 2007; 154: 441-447.
21. Ohuchi H, Watanabe K, Kishiki K, Wakisako Y, Echigo S. Heart rate dynamics during and after exercise in postoperative congenital heart disease patients. Their relation to cardiac autonomic nervous activity and intrinsic sinus node dysfunction. Am Heart J, 2007; 154: 165-171.
22. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med, 2001; 39: 571-588.
23. Book WM, Hott BJ, McConnel M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol, 2005; 95: 545-546.
24. Cowley CG, Bradley JD, Shaddy R.. B-type natriuretic peptide levels in congenital heart disease. Pediatr Catrdiol, 2004; 25: 336-340.
25. Nir A, Nasser N. Clinical value of NT-proBNP and BNP in pediatric cardiology. J Cardiac Fail, 2005; 5: 67-80.
26. Mir TS, Falkenberg J, Friedrich B et al. Levels off brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young, 2005; 15: 396-401.
27. Larsson DA, Meurling CJ, Holmqvist F, Waktare JEP, Thilen UJ. The diagnostic and prognostic value of brain natriuretic peptides in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol, 2007; 114: 345-351.
28. Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol, 2005; 95: 474-478.
29. Webb G, Horlick E. Lessons from cardiopulmonary testing after device closure of secundum atrial septal defect. J Am Coll Cardiol, 2004; 43: 1892-1893.
30. Norozi K, Wessel A, Cand VA et al. Chronotropic incompetence in adolescents and adults congenital heart disease after cardiac surgery. J Cardiac Fail, 2007; 13: 263-268.
31. Iserin L, Chua TP, Chambers J, Coats AJS, Somerville J. Dyspnea and exercise intolerance during cardiopulmonary exercise testing in patients with univentricular heart. Eur Heart J, 1997; 18: 1350-1356.
32. Passimo C, Sironi AM, Favili B et al. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. Int J Cardiol, 2004; 104: 39-45.
33. Yap LB. B-type natriuretic peptide and right heart. Heart Failure Rev, 2004; 9: 99-103.
34. Nagaya N, NIshikimi T, Uematsu M. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation, 2000; 87: 2345-2350.
35. Yap LB, Ashrafian H, Mukerjee D, Coghlan JG, Timms PM. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Bioch, 2004; 37: 847-856.
36. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adult patients with cyanotic congenital heart disease. Circulation, 2004; 109: 2878-2877.
37. Hopkins WE, Hall C. Paradoxical relationship between N-terminal proatrial natriuretic peptide and filling pressure in adults with cyanotic congenital heart disease. Circulation, 1997; 96: 2215-2220.
38. Holmgren D, Westerlind A, Lundberg PA, Wahlander H. Increased plasma levels of natriuretic peptide type A and B in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload. Clin Physiol Funct Imag, 2005; 25: 263-269.
39. Perlowski AA, Aboulhosn J, Castellon Y, Miner P, Child JS. Relation of brain natriuretic peptide to myocardial performance index in adult with congenital heart disease. Am J Cardiol, 2007; 100: 110-114.
40. Norozi K, Buchhorn R, Keiser C et al. Plasma N-terminal probrain natriuretic peptide as a marker of right vascular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest, 2005; 128: 2563-2570.
41. Fredriksen PM, Chen A, Veldtman G, Hechter S, Therrien J, Webb G. Exercise capacity in adult patients with congenitally corrected transposition of the great arteries. Heart, 2001; 85: 191-195.
42. Warnes CA. The adults with congenital heart disease. Born to be bad? J Am Coll Cardiol, 2005; 48: 1-8.